U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years... (patients six to 17 yearsof age with mode...)

HOME >> MEDICINE >> TECHNOLOGY

U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older

Date:4/8/2008

patients six to 17 years of age with moderately to severely active polyarticular JIA who had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs), such as MTX or TNF antagonists.

"Juvenile idiopathic arthritis is the most prevalent form of arthritis in children(3)," said Elliott Sigal, M.D., Ph.D., executive vice president, chief scientific officer and president, Research and Development, Bristol-Myers Squibb. "This new indication for ORENCIA offers another treatment option to help improve signs and symptoms of this serious disease in pediatric and adolescent patients."

In addition to the approval for JIA, Bristol-Myers Squibb has added a post-marketing safety section to the package insert. This section states that the post-marketing adverse event profile that was observed in adult RA patients did not differ from that seen in the clinical trials of adult RA patients. The FDA also has revised the adult indication to remove the requirement that patients must first fail at least one DMARD before initiating therapy with ORENCIA. The new indication statement is: ORENCIA is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage and improving physical function in adult patients with moderately to severely active RA. ORENCIA may be used as monotherapy or concomitantly with DMARDs other than TNF antagonists. ORENCIA should not be administered concomitantly with TNF antagonists and is not recommended for use concomitantly with other biologic RA therapy, such as anakinra. The revised adult indication means that ORENCIA is an appropriate option for patients with moderate-to-severe RA, regardless of prior treatment received.

ORENCIA JIA Study (AWAKEN Trial)

The AWAKEN trial was a three-part study which included patients with subtypes of JIA that at disease onset included Oligoarticular JIA (16 percent), Polyarticular JIA (64 percent; 20 percent were
'/>"/>

SOURCE Bristol-Myers Squibb Company
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10
Related medicine technology :

1. Ortho Biotech Statement on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Vote
2. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
3. Northwestern Offers Clinical Research and Regulatory Administration Graduate Certificate Program
4. Supplemental New Drug Application for PREZISTA(TM) Submitted to U.S. Food and Drug Administration
5. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
6. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
7. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
8. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
9. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
10. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
11. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV

Post Your Comments:

(Date:5/18/2013)... , May 18, 2013 Faruqi ... firm, is investigating potential securities fraud at AVEO ... (Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO ) ... and its executives violated federal securities laws by ... Company,s Phase III drug trials for Tivopath (tivozanib) ...

(Date:5/17/2013)... , May 17, 2013 Orexigen® Therapeutics, Inc. (Nasdaq: ... company overview at the UBS Global Healthcare Conference in ... Wednesday, May 22 nd at 11 a.m. Eastern Time. ... the presentation, please visit the Investor Relations section of the ... be available for 14 days after the event. ...

(Date:5/17/2013)... YORK , May 17, 2013 /PRNewswire-iReach/ -- United ... Advanced Cardiac Life Support (ACLS), Pediatric Advanced Life Support ... free PALS, BLS and ACLS online course ... manuals, people simply need to build an account with ... materials for these programs, United Medical Education is setting ...

Breaking Medicine Technology:Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm 2 ACLS Online Course Manuals are Now Available at No Cost through United Medical Education 2

[0] Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm [0] Orexigen Therapeutics to Present at the UBS Global Healthcare Conference [0] ACLS Online Course Manuals are Now Available at No Cost through United Medical Education

... BETHESDA, Md., April 14 Micromet, Inc.,(Nasdaq: ... novel, proprietary,antibodies for the treatment of cancer, ... meeting of the American Association for,Cancer Research ... that commercial,anti-cancer antibodies trastuzumab (Herceptin(R); Genentech, Roche),cetuximab ...

... the, Tumor Suppressor P53 Inhibited Tumor Growth Synergistically in Preclinical ... ... 14 ,Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) announced today that ... 2008 Annual Meeting of the American Association for Cancer Research,(AACR) further ...

Cached Medicine Technology:Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies 2 Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies 3 Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies 4 Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies 5 Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrine's anti-PS Vascular Targeting Antibodies 2 Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrine's anti-PS Vascular Targeting Antibodies 3 Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrine's anti-PS Vascular Targeting Antibodies 4

Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrine's anti-PS Vascular Targeting Antibodies

(Date:5/18/2013)... California (PRWEB) May 18, 2013 Online watch ... be Rolex watch owners at a fraction of ... of luxury timepieces in the world, buyers are urged to ... compared to buying a Rolex watch from a brick-and-mortar store, ... owned Rolex watches priced at unbelievable rates. Although some ...

(Date:5/18/2013)... Thompson HealthDay Reporter , , FRIDAY, May 17 ... the latest edition of what is considered the "bible" ... many changes continues. "This is unprecedented, the amount ... Lieberman, president-elect of the American Psychiatric Association (APA). "It,s ... it is. You have to evaluate it and then ...

(Date:5/18/2013)... (HealthDay News) -- Just a few extra cups of ... an autoimmune liver disease known as primary sclerosing cholangitis ... Mayo Clinic in Rochester, Minn., found that drinking coffee ... disease, which can lead to cirrhosis of the liver, ... not prove a cause-and-effect relationship. "While rare, ...

(Date:5/18/2013)... The use of a smartphone application significantly ... new research presented today at Digestive Disease Week ... advance of the procedure, includes dietary restrictions and ... at strict intervals. The better the preparation, the ... and precancerous polyps in the colon. The study, ...

(Date:5/18/2013)... ROCHESTER, Minn. -- Regular consumption of coffee is ... cholangitis (PSC), an autoimmune liver disease, Mayo Clinic ... the Digestive Disease Week 2013 conference in Orlando, ... of the bile ducts that results in inflammation ... of the liver, liver failure and biliary cancer. ...

Breaking Medicine News(10 mins):Health News:Time and Gems Offers Buyers the Largest Collection of Rolex Watches Yet 2 Health News:Time and Gems Offers Buyers the Largest Collection of Rolex Watches Yet 3 Health News:Latest Edition of Psychiatry's 'Bible' Launched Amid Controversy 2 Health News:Latest Edition of Psychiatry's 'Bible' Launched Amid Controversy 3 Health News:Latest Edition of Psychiatry's 'Bible' Launched Amid Controversy 4 Health News:Study Links Coffee to Lower Risk for Rare Liver Disease 2 Health News:New smartphone application improves colonoscopy preparation 2

[0] Time and Gems Offers Buyers the Largest Collection of Rolex Watches Yet [0] Latest Edition of Psychiatry's 'Bible' Launched Amid Controversy [0] Study Links Coffee to Lower Risk for Rare Liver Disease [0] New smartphone application improves colonoscopy preparation [0] Consuming coffee linked to lower risk of detrimental liver disease, Mayo Clinic finds

... - Exclusive, multi-year contract executed by Intercell and ... First sales of IXIARO under this military contract ... ICLL; OTC Bulletin Board: INRLY) announced today that ... contract with the Defense Logistics Agency (DLA), Defense ...

... Sunday, individuals all over the nation will be celebrating a ... life: their mothers. While people in the United States turn ... (IBMP) hopes to inspire some to also think of mothers ... the United States send their breast milk to infants in ...

... may be used someday against Parkinson,s, too, expert suggests, , , ... to lend a hand in the death of brain cells ... according to a newly published study. , ... normally guides molecules in and out of cells, but it ...

... and recovery fairly quick , , FRIDAY, May 8 (HealthDay News) ... from over, with hundreds of new cases being reported each day, ... issue that,s been concerning me, that has to do with a ... over," Dr. Richard Besser, acting director of the U.S. Centers for ...

... Almost Family, Inc. (Nasdaq: AFAM ), a ... that William Yarmuth, President and Chief Executive Officer, and Steve ... to present at two upcoming investor conferences. The first ... 2009 Growth Stock Conference at the Four Seasons Hotel in ...

... ANN ARBOR, Mich., May 8 Thomson Reuters on ... hospital system for significantly improving the quality and managing ... plans and Tallahassee Memorial HealthCare are overall winners of ... hospitals and healthcare payers that use data analytics to ...

Intercell Executes Multi-Year Contract for Supply of IXIARO(R) to the United States Military International Breast Milk Project Helps Mothers Worldwide Protein Might Mute Effects of Methamphetamine As Swine Flu Cases Mount, CDC Says U.S. Hasn't 'Dodged a Bullet'Almost Family to Present at Two Upcoming Conferences Thomson Reuters Honors Keystone Mercy and AmeriHealth Mercy Health Plans and Tallahassee Memorial HealthCare

Touch-Trol Pediatric Suction Catheter Mini-Tray...

SAFE-T-VAC Suction Catheter Kits with Protective Sleeve...

Our suction kits include a Tri-Flo® suction catheter, a pop-up solution basin and two sturdy, precuffed latex exam gloves in an inner wallet. Infant and pediatric kits (5/6, 8 and 10 Fr) feature ...

... kit includes a Tri-Flo® suction ... for flushing and lubrication, two ... inner wallet and a rigid ... (5/6, 8 and 10 Fr) ...

Medicine Products:

Touch-Trol Suction Pediatric Catheter Mini-Tray SAFE-T-VAC Suction Catheter Kits with Protective Sleeve AirLife™ Brand Cath-N-Glove® Suction Kits In Peel Pouch Rigid Suction Tray Kits With Saline